Hepalink USA to acquire Cytovance Biologics - MarketLine Financial Deals

Hepalink USA to acquire Cytovance Biologics

Hepalink USA to acquire Cytovance Biologics - MarketLine Financial Deals
Hepalink USA to acquire Cytovance Biologics
Published Aug 24, 2015
3 pages — Published Aug 24, 2015
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Hepalink USA, Inc., a wholly-owned subsidiary of Shenzhen Hepalink Pharmaceutical Co., Ltd., has entered into an agreement to acquire 100% stake in Cytovance Biologics, Inc.

  
Source:
Document ID
MA158521_150826
Country
Country
Ticker
002398=CN
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Hepalink USA to acquire Cytovance Biologics" Aug 24, 2015. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Hepalink-USA-to-acquire-Cytovance-Biologics-2052-112193>
  
APA:
MarketLine Financial Deals. (2015). Hepalink USA to acquire Cytovance Biologics Aug 24, 2015. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Hepalink-USA-to-acquire-Cytovance-Biologics-2052-112193>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.